PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Rang in Aktien #1425
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aktienkurs
$36.27
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$15.00B
Veränderung (1 Tag)
-1.24%
Veränderung (1 Jahr)
140.82%
Land
TW
Handel PharmaEssentia Corporation (6446)

Kategorie

Healthcare
Kursverlauf für PharmaEssentia Corporation (6446)
Höchster Schlusskurs: $37.54 am 2026-10-01

Niedrigster Schlusskurs: $4.95 am 2014-03-01
Kursverlauf der Aktie von PharmaEssentia Corporation von 2014 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 78.22%
2025 -1.54%
2024 65.30%
2023 -34.57%
2022 52.79%
2021 220.53%
2020 2.39%
2019 -41.63%
2018 21.23%
2017 -8.25%
2016 -3.31%
2015 21.68%
2014 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$171.67 -
DE
$161.15 20.52%
DE
$40.32 42.64%
JP
$212.49 24.09%
CH
$19.19 -0.09%
IN